JOURNAL ARTICLE

Authors recommend stronger standards for informed consent to receive psychedelics.

  • Published In: Brown University Psychopharmacology Update, 2024, v. 35, n. 8. P. 1 1 of 2

  • Database: Academic Search Ultimate 2 of 2

Abstract

The potential risks associated with administration of psychedelic drugs call for a standardized approach to patient informed consent that addresses factors such as potentially disturbing symptoms and the danger of patient exploitation, authors of a recently published article suggest. The diverse contexts for therapeutic use of these substances and the variety of providers potentially involved in their administration necessitate strong informed consent procedures, the authors explained. The special communication was published online April 10, 2024, in JAMA Psychiatry. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Brown University Psychopharmacology Update. 2024/08, Vol. 35, Issue 8, p1
  • Document Type:Article
  • Subject Area:Pharmacy and Pharmacology
  • Publication Date:2024
  • ISSN:1068-5308
  • DOI:10.1002/pu.31187
  • Accession Number:178131720
  • Copyright Statement:Copyright of Brown University Psychopharmacology Update is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.